Display options
Share it on

Pathogens. 2014 Jul 30;3(3):656-66. doi: 10.3390/pathogens3030656.

Development and validation of a rapid turbidimetric assay to determine the potency of cefuroxime sodium in powder for dissolution for injection.

Pathogens (Basel, Switzerland)

Daniela C M Vieira, Thalita F M Fiuza, Hérida R N Salgado

Affiliations

  1. Faculdade Pitágoras - Campus Poços de Caldas, Av. João Pinheiro, 1046, Poços de Caldas -MG 37701-014, Brazil. [email protected].
  2. Department of Drugs and Medicines, Faculty of Pharmaceutical Sciences, Universidade Estadual Paulista "Júlio de Mesquita Filho", Araraquara14800-901, SP, Brazil. [email protected].
  3. Department of Drugs and Medicines, Faculty of Pharmaceutical Sciences, Universidade Estadual Paulista "Júlio de Mesquita Filho", Araraquara14800-901, SP, Brazil. [email protected].

PMID: 25438016 PMCID: PMC4243433 DOI: 10.3390/pathogens3030656

Abstract

The cefuroxime sodium is a second generation cephalosporin indicated for infections caused by Gram-positive and Gram-negative microorganisms. Although this drug is highly studied and researched regarding the antimicrobial activity, pharmacokinetics and pharmacodynamics, there are few studies regarding the development of analytical methodology for this cephalosporin. Thus, research involving analytical methods is essential and highly relevant to optimize its analysis in the pharmaceutical industry and guarantee the quality of the product already sold. This study describes the development and validation of a microbiological assay applying the turbidimetric method for the determination of cefuroxime, using Micrococcus luteus ATCC 9341 as micro-organism test and 3x3 parallel line assay design, with nine tubes for each assay, as recommended by the Brazilian Pharmacopoeia. The developed and validated method showed excellent results of linearity, seletivity, precision and robustness, in the concentration range from 30.0 to 120.0 mg/mL, with 100.21% accuracy and content 99.97% to cefuroxime sodium in injectable pharmaceutical form.

References

  1. J Chromatogr A. 2011 Jul 29;1218(30):4972-81 - PubMed
  2. Antimicrob Agents Chemother. 1985 Feb;27(2):207-16 - PubMed
  3. J AOAC Int. 2006 May-Jun;89(3):642-5 - PubMed
  4. J AOAC Int. 2007 Nov-Dec;90(6):1724-8 - PubMed
  5. J AOAC Int. 2008 Jul-Aug;91(4):739-43 - PubMed
  6. J Chromatogr B Biomed Sci Appl. 1997 Mar 7;690(1-2):321-6 - PubMed
  7. Luminescence. 2009 Mar-Apr;24(2):102-7 - PubMed
  8. J AOAC Int. 2006 Sep-Oct;89(5):1305-8 - PubMed
  9. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Aug 5;775(2):239-46 - PubMed
  10. J Pharm Biomed Anal. 2002 Jun 20;29(1-2):347-54 - PubMed
  11. Am J Hosp Pharm. 1994 Feb 15;51(4):463-77; quiz 541-2 - PubMed
  12. J AOAC Int. 2007 Sep-Oct;90(5):1379-82 - PubMed
  13. J Pharm Biomed Anal. 1999 Dec;21(4):703-7 - PubMed
  14. J Chromatogr Sci. 2011 Aug;49(7):508-11 - PubMed

Publication Types